CL2016000042A1 - Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas. - Google Patents

Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas.

Info

Publication number
CL2016000042A1
CL2016000042A1 CL2016000042A CL2016000042A CL2016000042A1 CL 2016000042 A1 CL2016000042 A1 CL 2016000042A1 CL 2016000042 A CL2016000042 A CL 2016000042A CL 2016000042 A CL2016000042 A CL 2016000042A CL 2016000042 A1 CL2016000042 A1 CL 2016000042A1
Authority
CL
Chile
Prior art keywords
inhibitor
combination
treatment
hyperproliferative diseases
erk
Prior art date
Application number
CL2016000042A
Other languages
English (en)
Inventor
Marcia Belvin
John Moffat
Mark Merchant
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2016000042A1 publication Critical patent/CL2016000042A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

METODO PARA EL TRATAMIENTO DE UN TRASTORNO HIPERPROLIFERATIVO QUE COMPRENDE ADMINISTRAR UNA COMBINACIÓN DE UN INHIBIDOR DE MEK Y UN INHIBIDOR DE ERK; SU USO; Y KIT QUE COMPRENDE A LA COMBINACION.
CL2016000042A 2013-09-05 2016-01-08 Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas. CL2016000042A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361874206P 2013-09-05 2013-09-05

Publications (1)

Publication Number Publication Date
CL2016000042A1 true CL2016000042A1 (es) 2016-08-05

Family

ID=51492945

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000042A CL2016000042A1 (es) 2013-09-05 2016-01-08 Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas.

Country Status (21)

Country Link
US (1) US9532987B2 (es)
EP (1) EP3041471A1 (es)
JP (2) JP2016531139A (es)
KR (1) KR20160048807A (es)
CN (1) CN105517548B (es)
AR (1) AR097556A1 (es)
AU (1) AU2014317119B2 (es)
CA (1) CA2916619A1 (es)
CL (1) CL2016000042A1 (es)
EA (1) EA034872B1 (es)
HK (1) HK1218072A1 (es)
IL (1) IL243251B (es)
MA (1) MA38827A1 (es)
MX (1) MX370417B (es)
PE (1) PE20160529A1 (es)
PH (1) PH12016500270A1 (es)
SG (1) SG11201600989VA (es)
TW (1) TW201605477A (es)
UA (1) UA120423C2 (es)
WO (1) WO2015032840A1 (es)
ZA (1) ZA201600091B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20150666A1 (es) * 2012-03-01 2015-05-06 Array Biopharma Inc Inhibidores de serina/treonina cinasa
EA031243B1 (ru) 2013-12-06 2018-12-28 Дженентек, Инк. Ингибиторы серин/треонинкиназ
MX375902B (es) * 2013-12-30 2025-03-07 Genentech Inc Inhibidores de serina/treonina cinasa.
WO2016162325A1 (en) 2015-04-07 2016-10-13 Astrazeneca Ab Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1 (2h)-one derivatives as kinase inhibitors
WO2017080980A1 (en) 2015-11-09 2017-05-18 Astrazeneca Ab Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer
SMT202000152T1 (it) 2015-11-09 2020-05-08 Astrazeneca Ab Derivati di diidroimidazopirazinone utili nel trattamento di cancro
CN105330643B (zh) 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
AU2017249229A1 (en) * 2016-04-15 2018-10-04 Genentech, Inc. Diagnostic and therapeutic methods for cancer
KR20190039951A (ko) 2016-08-23 2019-04-16 제넨테크, 인크. 췌장암의 치료를 위한 병용요법
MX379222B (es) 2016-11-25 2025-03-10 Genuv Inc Composición para promover la diferenciación y protección de células madre neurales y método para inducir la regeneración neural usando las mismas.
JP2019019094A (ja) * 2017-07-19 2019-02-07 学校法人福岡大学 変異ｋｒａｓ関連シグナル阻害用組成物
KR102811888B1 (ko) 2017-09-08 2025-05-27 에프. 호프만-라 로슈 아게 암의 진단 및 치료 방법
US12435078B2 (en) 2017-09-18 2025-10-07 Gfb (Abc), Llc Pyridazinones and methods of use thereof
WO2019139970A1 (en) * 2018-01-09 2019-07-18 Duke University Topical administration of mek inhibiting agents for the treatment of skin disorders
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
WO2021007499A1 (en) * 2019-07-11 2021-01-14 Emory University Combination therapies for managing cancer
AR126166A1 (es) * 2021-06-18 2023-09-27 Antengene Discovery Ltd Combinación de un inhibidor de erk y un inhibidor de kras y usos de estos
KR102695469B1 (ko) * 2021-07-23 2024-08-14 차의과학대학교 산학협력단 2,4-디아미노피리미딘을 포함하는 암의 예방 또는 치료용 조성물
CN118001281B (zh) * 2023-12-11 2025-10-17 中国科学院深圳先进技术研究院 一种治疗或预防甲基苯丙胺成瘾的药物及应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
WO2008024724A1 (en) 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
CA2660546A1 (en) 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
CA2672327A1 (en) 2006-11-30 2008-06-05 Genentech, Inc. Aza-indolyl compounds and methods of use
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
EP2164850B1 (en) 2007-06-12 2016-01-13 Genentech, Inc. N-substituted azaindoles and methods of use
EP2231662B1 (en) 2007-12-19 2011-06-22 Genentech, Inc. 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
TWI441820B (zh) 2007-12-19 2014-06-21 Genentech Inc ５－苯胺咪唑并吡啶及使用方法
CA2708176A1 (en) 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines and methods of use
CA2727250A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Bicyclic heterocycles as mek kinase inhibitors
JP5615274B2 (ja) 2008-07-01 2014-10-29 ジェネンテック， インコーポレイテッド Ｍｅｋキナーゼインヒビターとしてのイソインドロン誘導体及びその使用方法
CN102859355B (zh) 2009-08-24 2015-10-07 基因泰克公司 通过检测kras突变和rtk表达水平来测定细胞对b-raf抑制剂治疗的敏感性
AU2010314287A1 (en) 2009-10-12 2012-05-03 F. Hoffmann-La Roche Ag Combinations of a PI3K inhibitor and a MEK inhibitor
WO2012071336A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Salts and crystalline forms of an apoptosis-inducing agent
US9133187B2 (en) 2011-02-28 2015-09-15 Array Biopharma Inc. Serine/threonine kinase inhibitors
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
ES2552989T3 (es) 2011-08-04 2015-12-03 Array Biopharma, Inc. Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina
PE20150666A1 (es) 2012-03-01 2015-05-06 Array Biopharma Inc Inhibidores de serina/treonina cinasa
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CN104363908B (zh) 2012-05-30 2017-12-22 霍夫曼-拉罗奇有限公司 吡咯烷基杂环类
DK2884979T3 (da) 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
CA2882750A1 (en) 2012-08-27 2014-03-06 Jim Blake Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
SI2909188T1 (en) 2012-10-12 2018-07-31 Exelixis, Inc. A novel process for the manufacture of compounds for use in the treatment of cancer
EP2909206A1 (en) 2012-10-16 2015-08-26 F. Hoffmann-La Roche AG Serine/threonine kinase inhibitors
EA031243B1 (ru) 2013-12-06 2018-12-28 Дженентек, Инк. Ингибиторы серин/треонинкиназ
MX375902B (es) 2013-12-30 2025-03-07 Genentech Inc Inhibidores de serina/treonina cinasa.
KR102379517B1 (ko) 2013-12-30 2022-03-25 제넨테크, 인크. 세린/트레오닌 키나아제 억제제
CN106659721B (zh) 2014-04-09 2021-01-01 基因泰克公司 用于制备药物的方法

Also Published As

Publication number Publication date
KR20160048807A (ko) 2016-05-04
AU2014317119B2 (en) 2019-12-05
WO2015032840A1 (en) 2015-03-12
EP3041471A1 (en) 2016-07-13
AR097556A1 (es) 2016-03-23
CN105517548A (zh) 2016-04-20
UA120423C2 (uk) 2019-12-10
US9532987B2 (en) 2017-01-03
MX2016002857A (es) 2016-06-22
PE20160529A1 (es) 2016-05-21
PH12016500270A1 (en) 2016-05-16
CN105517548B (zh) 2020-01-21
SG11201600989VA (en) 2016-03-30
MA38827A1 (fr) 2017-10-31
AU2014317119A1 (en) 2016-03-03
HK1218072A1 (zh) 2017-02-03
EA034872B1 (ru) 2020-03-31
EA201690513A1 (ru) 2016-07-29
US20150111869A1 (en) 2015-04-23
JP2016531139A (ja) 2016-10-06
IL243251B (en) 2019-02-28
ZA201600091B (en) 2017-04-26
TW201605477A (zh) 2016-02-16
MX370417B (es) 2019-12-10
JP2019031517A (ja) 2019-02-28
CA2916619A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CL2016001586A1 (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
CL2016000925A1 (es) Inhibidores de bromodominio
PT3218005T (pt) Compostos que interagem com glicano e métodos de uso
PL2976106T3 (pl) Terapia kombinowana obejmująca inhibitor B-Raf i drugi inhibitor
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CR20150462A (es) Inhibidores de erk y sus usos
MX2017001512A (es) Compuestos activos hacia bromodominios.
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
MX2017005555A (es) Inhibidores del bromodominio.
ECSP13012394A (es) Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
BR112013027716A2 (pt) gavetas rápidas com rolos e rampa
UY4211Q (es) Pizarra para marcadores
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
BR112015030351A2 (pt) método e aparelho para realização de transações locais
MX2019009908A (es) Combinacion de un agonista de ppar con un agonista de fxr.
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
CL2016001098A1 (es) Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales
TWD171584S (zh) 自動出入閘門
SG10201405683YA (en) Emission Source And Method Of Forming The Same
HRP20181301T1 (hr) Herbicidna kombinacija koja sadrži pelargonijsku kiselinu i inhibitore als
PT2968083T (pt) Composição dentária que compreende quelante e base
CL2015002181A1 (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod.